Amylyx 制药

最新新闻

• Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Baird Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  H.C. Wainwright Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/7/2
• 评级变动
  Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $24 to $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  TD Cowen Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 评级变动
  Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 评级变动
  LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Heart Test Laboratories, Inc. (HSCS) and Align Tech (ALGN)
  TipRanks · 2026/7/30
• LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/23
• 评级变动
  Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• 评级变动
  Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN)
  TipRanks · 2026/7/2
• 评级变动
  Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• Stifel Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/19

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。